Altimmune reports Phase IIa data for intranasal influenza vaccine

Altimmune Inc. (NASDAQ:ALT) reported data from a Phase IIa trial in 60 healthy volunteers showing that the two highest doses of its recombinant intranasal influenza vaccine NasoVAX led to 100% seroprotection. The company also said that mean antibody titers against influenza as measured by hemagglutination inhibition (HAI) and microneutralization assays increased by up to 4.3-fold. NasoVAX was well tolerated with no serious adverse events reported in the double-blind, placebo-controlled, U.S. trial...